Author

Bjoern Papke

German Cancer Research CenterORCID 0000-0001-8156-7508Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 3 Approach:experimental assay· 3 Organism:human· 3 Assay:proteomics· 3 Assay:metabolomics· 2 Organism:mouse· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

Channing J. DeriD· 2 shared Christine SersiD· 2 shared David A. HorstiD· 2 shared Tamara IsermanniD· 2 shared Adrienne D. CoxiD· 1 shared Alexandra TrinksiD· 1 shared Andrew M. WatersiD· 1 shared Bertram KlingeriD· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Channing J. DerORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivPreprintAug 11, 2026

Concurrent AXL inhibition enhances RAS and ERK inhibitor efficacy in KRAS-mutant pancreatic and lung cancer

Yan Ming Ching, Shruthi Narayanan, Jeffrey A. Klomp…·Bjoern Papke

This study shows that combining AXL inhibition with RAS or ERK inhibitors enhances efficacy in KRAS-mutant cancers by overcoming resistance mechanisms.

1 citation

humanmouse

𝕏 PostBluesky

Cancer BiologyScience SignalingPeer-reviewedJul 22, 2025

Reporter-based screening identifies RAS-RAF stabilizing mutations as drivers of resistance to broad-spectrum RAS inhibition in colorectal cancer

Oleksandra Aust, Moritz R. T. Thiel, Eric Blanc…·Markus Morkel

5 citations

humanproteomics

𝕏 PostBluesky

Cancer BiologyCell Death and DifferentiationPeer-reviewedApr 9, 2025

Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibition

Tamara Isermann, Kim Lucia Schneider, Florian Wegwitz…·Ramona Schulz‐Heddergott

This study shows that combining HSP90 inhibitors with p53 activation or CDK4/6 inhibition enhances colorectal cancer therapy by disrupting the HSF1-HSR feedback loop.

19 citationstop 4%

mousehuman

𝕏 PostBluesky